AbbVie Inc.
ABBVNYSEHealthcare● Active
$227.23
+$2.29(+1.02%)
Market Cap$401.5B
P/E Ratio—
52W High$244.81
52W Low$181.73
AbbVie Inc.（ABBV）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · ABBV · 截至 2026-06-08
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $4.23B | $4.29B | $4.82B | $11.85B | $11.55B |
| Depreciation & Amort. | $8.14B | $8.39B | $8.70B | $8.47B | $8.52B |
| Stock-Based Comp. | $0.95B | $0.91B | $0.75B | $0.67B | $0.69B |
| Change in Working Capital | ($2.36B) | ($2.78B) | $2.81B | ($0.26B) | ($1.32B) |
| Net Cash from Operations | $19.03B | $18.81B | $22.84B | $24.94B | $22.78B |
| Investing Activities | |||||
| Capital Expenditure | ($1.21B) | ($0.97B) | ($0.78B) | ($0.69B) | ($0.79B) |
| Purchases of Investments | ($0.04B) | ($0.07B) | ($0.08B) | ($1.44B) | ($0.12B) |
| Sales of Investments | $0.08B | $0.56B | $0.06B | $1.53B | $0.10B |
| Net Cash from Investing | ($6.64B) | ($20.82B) | ($2.01B) | ($0.62B) | ($2.34B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.98B) | ($1.71B) | ($1.97B) | ($1.49B) | ($0.93B) |
| Dividends Paid | ($11.66B) | ($11.03B) | ($10.54B) | ($10.04B) | ($9.26B) |
| Debt Issued / Repaid | ($0.33B) | $7.35B | ($4.15B) | ($12.43B) | ($8.41B) |
| Net Cash from Financing | ($12.72B) | ($5.21B) | ($17.22B) | ($24.80B) | ($19.04B) |
| Free Cash Flow | |||||
| Free Cash Flow | $17.82B | $17.83B | $22.06B | $24.25B | $21.99B |
| FCF Margin %(computed) | 29.13% | 31.65% | 40.62% | 41.77% | 39.13% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解AbbVie Inc.
关于AbbVie Inc.（ABBV）现金流量表
AbbVie Inc. 2025财年经营活动现金流$19.03B，自由现金流$17.82B（FCF利润率29.13%），资本支出($1.21B)。
常见问题
ABBV · 4 问AbbVie Inc. 2025财年自由现金流$17.82B，同比down0.1%。
ABBV free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08